Retinal hyperspectral imaging in mouse models of Parkinson’s disease and healthy aging

• Published in: Scientific reports Vol. 14; no. 1; pp. 16089 - 14
• Main Authors: Trlin, Paul, Gong, Jenny, Tran, Katie K. N., Wong, Vickie H. Y., Lee, Pei Ying, Hoang, Anh, Zhao, Da, Beauchamp, Leah C., Lim, Jeremiah K. H., Metha, Andrew, Barnham, Kevin J., Finkelstein, David I., Bui, Bang V., Bedggood, Phillip, Nguyen, Christine T. O.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 12.07.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 631/378; 692/53; A53T; Ageing; Aging; alpha-Synuclein - genetics; alpha-Synuclein - metabolism; Alzheimer's disease; Animal models; Animals; Disease Models, Animal; Healthy Aging - metabolism; Humanities and Social Sciences; Humans; Hyperspectral; Hyperspectral Imaging - methods; Iron; Iron - metabolism; Male; Mice; Mice, Knockout; Mice, Transgenic; multidisciplinary; Neurodegenerative diseases; Neuroimaging; Parkinson Disease - diagnostic imaging; Parkinson Disease - genetics; Parkinson Disease - metabolism; Parkinson Disease - pathology; Parkinson's disease; Retina; Retina - diagnostic imaging; Retina - metabolism; Retina - pathology; Science; Science (multidisciplinary); Synuclein; Tau protein; TauKO; Wavelengths; TauKO; A53T; Alzheimer’s disease; Hyperspectral; Ageing; Parkinson’s disease
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-66284-7

Retinal hyperspectral imaging (HSI) is a non-invasive in vivo approach that has shown promise in Alzheimer’s disease. Parkinson’s disease is another neurodegenerative disease where brain pathobiology such as alpha-synuclein and iron overaccumulation have been implicated in the retina. However, it remains unknown whether HSI is altered in in vivo models of Parkinson’s disease, whether it differs from healthy aging, and the mechanisms which drive these changes. To address this, we conducted HSI in two mouse models of Parkinson’s disease across different ages; an alpha-synuclein overaccumulation model (hA53T transgenic line M83, A53T) and an iron deposition model (Tau knock out, TauKO). In comparison to wild-type littermates the A53T and TauKO mice both demonstrated increased reflectivity at short wavelengths ~ 450 to 600 nm. In contrast, healthy aging in three background strains exhibited the opposite effect, a decreased reflectance in the short wavelength spectrum. We also demonstrate that the Parkinson’s hyperspectral signature is similar to that from an Alzheimer’s disease model, 5xFAD mice. Multivariate analyses of HSI were significant when plotted against age. Moreover, when alpha-synuclein, iron or retinal nerve fibre layer thickness were added as a cofactor this improved the R 2 values of the correlations in certain groups. This study demonstrates an in vivo hyperspectral signature in Parkinson’s disease that is consistent in two mouse models and is distinct from healthy aging. There is also a suggestion that factors including retinal deposition of alpha-synuclein and iron may play a role in driving the Parkinson’s disease hyperspectral profile and retinal nerve fibre layer thickness in advanced aging. These findings suggest that HSI may be a promising translation tool in Parkinson’s disease.